<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02838472</url>
  </required_header>
  <id_info>
    <org_study_id>0631-15-HMO</org_study_id>
    <nct_id>NCT02838472</nct_id>
  </id_info>
  <brief_title>Ascorbic Acid Treatment in Congenital Glucocorticoids and Mineralocorticoids Deficiency Due to NNT Mutation</brief_title>
  <official_title>Ascorbic Acid Treatment for Patients With Combined Mineralocorticoid and Glucocorticoid Deficiency Secondary to Nicotinamide Nucleotide Transhydrogenase Mutation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hadassah Medical Organization</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Soroka University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hadassah Medical Organization</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Nicotinamide nucleotide transhydrogenase (NNT) mutations cause glucocorticoid and&#xD;
      mineralocorticoid deficiencies through decreased detoxification of reactive oxygen species&#xD;
      (ROS) in adrenocortical cells.&#xD;
&#xD;
      Ascorbic acid is well known by its high antioxidant activity due to the neutralization of&#xD;
      free radicals and other reactive oxygen species.&#xD;
&#xD;
      Preliminary results of NNT_p.G200S homozygous fibroblasts' treatment with 10 micro molar&#xD;
      L-ascorbic acid shows significant improvement in mitochondrial morphology and in ROS content.&#xD;
&#xD;
      The aim of this study is to figure out if ascorbic acid treatment improves the phenotype of&#xD;
      NNT patients by reducing ROS in their adrenocortical cells and preventing their apoptosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Most cases of familial glucocorticoid and mineralocorticoid deficiency are caused by&#xD;
      mutations interrupting steroidogenesis such as 21- hydroxylase deficiency. Recently,&#xD;
      nicotinamide nucleotide transhydrogenase (NNT) mutations were found to cause isolated&#xD;
      glucocorticoid deficiency or combined mineralocorticoid and glucocorticoid deficiency through&#xD;
      decreased detoxification of reactive oxygen species (ROS) in adrenocortical cells.&#xD;
&#xD;
      NNT mutation in mice causes also glucose intolerance. Ascorbic acid is an essential&#xD;
      water-soluble vitamin with excellent reducing properties, well known by its high antioxidant&#xD;
      activity due to the neutralization of free radicals and other reactive oxygen species. This&#xD;
      vitamin acts as the first line of defense during oxidative stress in the human body.&#xD;
&#xD;
      Ascorbic acid treatment for variant disease (e.g. - cancer, type 2 diabetes, anxiety,&#xD;
      depression, asthma and cardiovascular diseases) have been meticulously studies with no major&#xD;
      adverse effects.&#xD;
&#xD;
      In a previous study, the investigators demonstrated a higher ROS levels, a lower ATP content&#xD;
      and a change in mitochondrial morphology in NNT_p.G200S homozygous fibroblasts compared with&#xD;
      control fibroblasts.&#xD;
&#xD;
      Preliminary results of NNT_p.G200S homozygous fibroblasts' treatment with 10 micro molar&#xD;
      L-ascorbic acid shows significant improvement in mitochondrial morphology and in ROS content.&#xD;
&#xD;
      The aim of this study is to figure out if ascorbic acid treatment improves the phenotype of&#xD;
      NNT patients by reducing ROS in their adrenocortical cells and preventing their apoptosis.&#xD;
&#xD;
      During the study NNT_p.G200S homozygous patients (no.-3) will be hospitalised for ACTH and&#xD;
      OGTT tests and start ascorbic acid treatment at a doses of 75-80% of the upper limit of&#xD;
      allowance according to IOM. ACTH and OGTT will be repeated 6 months later to assess&#xD;
      improvement in glucocorticoids production and insulin resistance.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>glucocorticoids secretion in response to ACTH test</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>basal ACTH levels</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>insulin and glucose levels in OGTT</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">3</enrollment>
  <condition>Glucocorticoids Deficiency</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ascorbic Acid</intervention_name>
    <description>Ascorbic acid administration at a doses of 75-80% of the upper limit of allowance according to IOM</description>
    <other_name>Vitamin C</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  NNT mutation homozygous patients with glucocorticoids deficiency&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hadassah medical center</name>
      <address>
        <city>Jerusalem</city>
        <zip>99305</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <reference>
    <citation>Meimaridou E, Kowalczyk J, Guasti L, Hughes CR, Wagner F, Frommolt P, NÃ¼rnberg P, Mann NP, Banerjee R, Saka HN, Chapple JP, King PJ, Clark AJ, Metherell LA. Mutations in NNT encoding nicotinamide nucleotide transhydrogenase cause familial glucocorticoid deficiency. Nat Genet. 2012 May 27;44(7):740-2. doi: 10.1038/ng.2299.</citation>
    <PMID>22634753</PMID>
  </reference>
  <reference>
    <citation>Institute of Medicine (US) Panel on Dietary Antioxidants and Related Compounds. Dietary Reference Intakes for Vitamin C, Vitamin E, Selenium, and Carotenoids. Washington (DC): National Academies Press (US); 2000.</citation>
    <PMID>25077263</PMID>
  </reference>
  <results_reference>
    <citation>Weinberg-Shukron A, Abu-Libdeh A, Zhadeh F, Carmel L, Kogot-Levin A, Kamal L, Kanaan M, Zeligson S, Renbaum P, Levy-Lahad E, Zangen D. Combined mineralocorticoid and glucocorticoid deficiency is caused by a novel founder nicotinamide nucleotide transhydrogenase mutation that alters mitochondrial morphology and increases oxidative stress. J Med Genet. 2015 Sep;52(9):636-41. doi: 10.1136/jmedgenet-2015-103078. Epub 2015 Jun 12.</citation>
    <PMID>26070314</PMID>
  </results_reference>
  <verification_date>June 2016</verification_date>
  <study_first_submitted>July 17, 2016</study_first_submitted>
  <study_first_submitted_qc>July 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2016</study_first_posted>
  <last_update_submitted>July 19, 2016</last_update_submitted>
  <last_update_submitted_qc>July 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ascorbic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

